靶向血液系统恶性肿瘤中的调控细胞死亡（RCD）：最新进展与治疗潜力。
Targeting regulated cell death (RCD) in hematological malignancies: Recent advances and therapeutic potential.
机构信息
Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250021, China.
Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250021, China; Department of Hematology, Shandong Provincial Hospital, Shandong University, Jinan, Shandong 250021, China; Medical Science and Technology Innovation Center, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan 250117, China; Branch of National Clinical Research Center for Hematologic Diseases, Jinan, Shandong 250021, China; National Clinical Research Center for Hematologic Diseases, the First Affiliated Hospital of Soochow University, Suzhou 251006, China.
出版信息
Biomed Pharmacother. 2024 Jun;175:116667. doi: 10.1016/j.biopha.2024.116667. Epub 2024 May 3.
Regulated cell death (RCD) is a form of cell death that can be regulated by numerous biomacromolecules. Accumulating evidence suggests that dysregulated expression and altered localization of related proteins in RCD promote the development of cancer. Targeting subroutines of RCD with pharmacological small-molecule compounds is becoming a promising therapeutic avenue for anti-tumor treatment, especially in hematological malignancies. Herein, we summarize the aberrant mechanisms of apoptosis, necroptosis, pyroptosis, PANoptosis, and ferroptosis in hematological malignancies. In particular, we focus on the relationship between cell death and tumorigenesis, anti-tumor immunotherapy, and drug resistance in hematological malignancies. Furthermore, we discuss the emerging therapeutic strategies targeting different RCD subroutines. This review aims to summarize the significance and potential mechanisms of RCD in hematological malignancies, along with the development and utilization of pertinent therapeutic strategies.
调控性细胞死亡（RCD）是一种可被多种生物大分子调控的细胞死亡形式。越来越多的证据表明，RCD 中相关蛋白的失调表达和定位改变促进了癌症的发展。用药理学小分子化合物靶向 RCD 的子程序正成为抗肿瘤治疗的一种有前途的治疗途径，特别是在血液恶性肿瘤中。在此，我们总结了血液恶性肿瘤中细胞凋亡、坏死性凋亡、细胞焦亡、PANoptosis 和铁死亡的异常机制。特别是，我们重点关注细胞死亡与肿瘤发生、血液恶性肿瘤中的抗肿瘤免疫治疗和耐药性之间的关系。此外，我们还讨论了针对不同 RCD 子程序的新兴治疗策略。本综述旨在总结 RCD 在血液恶性肿瘤中的意义和潜在机制，以及相关治疗策略的发展和利用。
Zotero 插件